CANCER BEATERS

Are "Super Responders" Special?

S A MEDICAL STUDENT in the 1980s, Isaac "Zak" Kohane heard stories—from patients, mentors, and colleagues—of nearly miraculous recoveries from cancer. A patient given weeks to live instead survives for years. An experimental drug works exceptionally well—in only one patient. Or, most controversially, a patient rejects chemotherapy, radiation, and surgery, and somehow lives. As a trainee, Kohane found many such stories quite literally unbelievable. "Frankly," he says, "I assumed that they didn't really have a cancer."

Now Nelson professor of biomedical informatics at Harvard Medical School (see "Toward Precision Medicine," May-June 2015, page 17), Kohane not only believes

these stories, he's seeking them out. A year ago, he began a project to find "exceptional responders" to cancer treatment—those who have beaten the cancer odds many times over—in order to figure out what makes them special.

He was inspired initially by a very different group of patients. Since 2014, Kohane has coordinated a nationwide program to study and aid patients whose affliction with rare, undiagnosed diseases mark them as statistical outliers. "Outliers, by definition, are interesting," he explains, because they are different from everybody else, "so there are things to be learned. By finding these outliers, we have been able to make breakthroughs both for the patient but also scientifically," diagnosing more than

"as well as new and persistent forms of inequality. Our questions are also different: the political and economic instability that has followed the financial crisis of 2007-08 means that the worth of capitalism and the possibility of socialism are on the political agenda in ways they haven't been for decades." The Rawlsian tradition hasn't provided a path to realizing its goals of redistribution, and in an age of dramatic inequality, Forrester says, that is no longer enough. It also has little to contribute to newly urgent questions, such as the future of work, which has been unsettled by radical shifts in contingent labor and automation. "Should we characterize the data we provide to Facebook as a form of work?" Forrester asks. "What do philosophers think of as the big political puzzles of our time? The answer should not be the same as 'what Rawls thought." ∼MARINA N. BOLOTNIKOVA

creasingly short-term and precarious types

of work (see "How U.S. Companies Stole

American Jobs" July-August 2017, page 10),

KATRINA FORRESTER WEBSITE:

scholar.harvard.edu/katrinaforrester



toptieradmissions.com 781,530,7088 info@toptieradmissions.com



A SURE THING

Give and receive with a Charitable Gift Annuity to help alleviate suffering and improve health and well-being for all.

CGA Rates:

Rates vary by age

Age 60: 4.9% | Age 70: 6% | Age 80: 7.7%

Calculate your fixed income for life with our free gift calculator:


hms.harvard.edu/giftcalculator or call 1-800-922-1782

300 patients suffering from newly discovered genetic diseases in five years.

By investigating exceptional responders, Kohane now hopes to find new paths to cancer treatment, rather than new diseases. The study has thus far recruited more than 75 participants from around the United States, representing 24 different types of cancer. Many of the subjects responded exceptionally well to a conventional combination of surgery, radiation, and chemotherapy; others took part in clinical trials of new therapies, and were profoundly successful. At least one survived

with no conventional therapy at all. By collecting as much data as possible from these patients—sequencing their DNA, inventorying their gut microbes, and even asking them for access to data from their socialmedia pages and FitBit fitness trackers—Kohane hopes to draw connections between their successes and the underlying causes that may have saved them.

Such comprehensive study, he says, is possible in large part because of recent medical advances, not only in the genetic sequencing that will give the researchers gigabytes of



shared exposure to a particular infectious disease long before cancer struck. "Doctors, human beings, will look for individual things," says Kohane. "These programs are looking for *everything*."

Of course, there's a sizable gap between finding something a few exceptional responders have in common and understanding whether—and how—that explains their success. "Certain kinds of associations will be indistinguishable from a fluke," he says, especially when they pertain only to a handful of participants. "For those rare cases,

"We get letters from patients saying, 'I've been wondering why I alone of all my cohort in this clinical trial survived."

data about the participants' genomes, tumors, microbiomes, and immune systems, but also in the machine-learning systems that make it possible to sift through all that biometric data, and other, more narrative information. "Some of our patients," Kohane points out, "will have hundreds if not thousands of pages detailing their [medical] history." He aims to use automated systems to sift through those histories for common elements, to make connections that unaided humans couldn't—for example, noticing a

we'll have to find a mechanism, something that actually explains the association."

But he also hopes the study will find some trait that many exceptional responders possess, across their different cancer types. "We think in addition to the smattering of exceptional but rare [responses], there will be some common mechanism for a subset of these patients that will have to do either with the immune system or with the way it manages chromosomal instability" (the ability to repair DNA copying errors).

Technological advances aside, though, Kohane says the study has also been enabled and inspired by a newly powerful trend affecting and directing medical research. "The notion of patient-driven, advocacy-driven medicine is very different from the paternalistic view of medicine of even 30 years ago," he explains. He describes the exceptional responders—eager to share their health data for research, with little or no benefit to themselves—as "data altruists." Though he's careful to warn them that genetic information is difficult to keep entirely anonymous, and the data, though not public, will be shared widely with other researchers, "They're urgently passionate that we need to look at them.'

To empower this altruistic impulse, the exceptional-responder study will give participants access to all the data it collects on them, to discuss with their own physicians, or share with other studies. But Kohane says they see another benefit of joining the study. "We get letters from patients saying, T've been wondering why I alone of all my cohort in this clinical trial survived," he explains. "This is giving meaning to their experience, that maybe their experience could actually help others." —BENNETT MCINTOSH

ISAAC KOHANE WEBSITE:

www.zaklab.org